Lantheus Holdings Inc
LNTH54.900USD
-0.600-1.08%
Close 08/29, 16:00（ET）Quotes delayed by 15 min
3.73BMarket Cap
14.68P/E TTM
More Details of Lantheus Holdings Inc Company
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
Company Info
Ticker SymbolLNTH
Company nameLantheus Holdings Inc
IPO dateJun 25, 2015
CEOMr. Brian A. Markison
Number of employees808
Security typeOrdinary Share
Fiscal year-endJun 25
Address331 Treble Cove Road
CityNORTH BILLERICA
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01862
Phone19786718001
Websitehttps://www.lantheus.com/
Ticker SymbolLNTH
IPO dateJun 25, 2015
CEOMr. Brian A. Markison
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+34.47%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+450.62%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Jamie Spaeth
Ms. Jamie Spaeth
Chief People Officer
Chief People Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.03%
Janus Henderson Investors
10.21%
The Vanguard Group, Inc.
10.03%
Fidelity Management & Research Company LLC
6.08%
Farallon Capital Management, L.L.C.
4.88%
Other
57.78%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.03%
Janus Henderson Investors
10.21%
The Vanguard Group, Inc.
10.03%
Fidelity Management & Research Company LLC
6.08%
Farallon Capital Management, L.L.C.
4.88%
Other
57.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor
57.48%
Investment Advisor/Hedge Fund
45.03%
Hedge Fund
6.89%
Research Firm
3.61%
Individual Investor
2.32%
Pension Fund
1.94%
Bank and Trust
1.50%
Sovereign Wealth Fund
0.74%
Venture Capital
0.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1039
82.20M
120.88%
-4.84M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
2023Q2
790
72.85M
106.61%
-3.94M
2023Q1
733
71.94M
105.47%
-6.73M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.79M
11.27%
+17.69K
+0.23%
Mar 31, 2025
Janus Henderson Investors
6.26M
9.05%
-252.58K
-3.88%
May 30, 2025
The Vanguard Group, Inc.
6.99M
10.1%
-242.63K
-3.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.17M
3.14%
+148.84K
+7.36%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.02M
8.71%
+707.00K
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
2.64M
3.81%
-4.26K
-0.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.78M
2.57%
+94.57K
+5.62%
Mar 31, 2025
Wellington Management Company, LLP
909.10K
1.31%
+685.29K
+306.19%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.59M
2.3%
+34.05K
+2.19%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.41M
2.04%
-96.91K
-6.42%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
Invesco S&P MidCap 400 GARP ETF
2.15%
Harbor Health Care ETF
2.04%
Alpha Architect US Quantitative Value ETF
1.96%
SPDR S&P Health Care Equipment ETF
1.85%
Distillate Small/Mid Cash Flow ETF
1.13%
Invesco S&P MidCap 400 Pure Growth ETF
1.12%
Janus Henderson US Sustainable Equity ETF
1.12%
Fidelity Stocks for Inflation ETF
1.09%
Pacer US Cash Cows Growth ETF
0.75%
First Trust Small Cap US Equity Select ETF
0.68%
View more
Invesco S&P MidCap 400 GARP ETF
Proportion2.15%
Harbor Health Care ETF
Proportion2.04%
Alpha Architect US Quantitative Value ETF
Proportion1.96%
SPDR S&P Health Care Equipment ETF
Proportion1.85%
Distillate Small/Mid Cash Flow ETF
Proportion1.13%
Invesco S&P MidCap 400 Pure Growth ETF
Proportion1.12%
Janus Henderson US Sustainable Equity ETF
Proportion1.12%
Fidelity Stocks for Inflation ETF
Proportion1.09%
Pacer US Cash Cows Growth ETF
Proportion0.75%
First Trust Small Cap US Equity Select ETF
Proportion0.68%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
